Sugi Predict

Sugi Predict / Compounds / SCHEMBL377145

SCHEMBL377145

SCHEMBL377145

CC(=O)N[C@@H](CS)C(=O)OC(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ THRB P10828 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ PTGS2 P35354 1/20 0.57
▸ THPO P40225 1/20 0.57
▸ RECQL P46063 1/20 0.57
▸ BLM P54132 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.41
▸ ACE P12821 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.37
▸ TRPV1 Q8NER1 1/20 0.36
▸ NPR3 P17342 1/20 0.33
▸ FNTA P49354 1/20 0.31
▸ FNTB P49356 1/20 0.31
▸ MTNR1A P48039 3/20 0.31
▸ MTNR1B P49286 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377144 1.00 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL8943683 1.00 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL24374500 0.93 KDM4E (0.50) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL26945874 0.86 KDM4E (0.50) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL26946176 0.85 KDM4E (0.53) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL24669337 0.85 KDM4E (0.53) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL26946171 0.85 KDM4E (0.53) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL24359845 0.84 KDM4E (0.52) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL22557757 0.84 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL22557755 0.84 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255843-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC 2025-08-14 — — US claimed
EP-4561372-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC (US) 2025-06-04 — — EP claimed
WO-2024026124-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF PETERSON MATTHEW (US) 2024-02-01 — — WO claimed
EP-4054553-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS Retina Foundation of the Southwest (US) 2022-09-14 — — EP claimed
US-RE41339-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2010-05-18 — — US claimed
US-20030229141-A1 N-acetyl cysteine and its topical use YU RUEY J (US) 2003-12-11 — — US claimed
US-20250255843-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC 2025-08-14 — — US disclosed
EP-4561372-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC (US) 2025-06-04 — — EP disclosed
WO-2024205472-A1 COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF HUMAN TRANSTHYRETIN AMYLOIDOSIS OLOFSSON ANDERS (SE) 2024-10-03 — — WO disclosed
US-12011496-B2 Topical macqui berry formulation Tracie Martyn International, Inc. (US) 2024-06-18 — — US disclosed
WO-2024026124-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF PETERSON MATTHEW (US) 2024-02-01 — — WO disclosed
US-20220105017-A1 TOPICAL MACQUI BERRY FORMULATION TRACIE MARTYN INT INC (US) 2022-04-07 — — US disclosed
US-10993897-B2 Topical macqui berry formula Tracie Martyn International, Inc. (US) 2021-05-04 — — US disclosed
US-20060216251-A1 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-09-28 — — US disclosed
WO-2006026713-A2 TOPICAL BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-03-09 — — WO disclosed
US-20060045896-A1 Topical compositions comprising benfotiamine and pyridoxamine TRACIE MARTYN INTERNATIONAL, LLC 2006-03-02 — — US disclosed
US-20030229141-A1 N-acetyl cysteine and its topical use YU RUEY J (US) 2003-12-11 — — US disclosed
EP-0499882-B1 Pharmaceutical compositions containing N-acetyl-cysteine derivatives useful for the treatment of cataracts ZAMBON SPA (IT) 1997-04-09 — — EP disclosed
US-5519054-A APPLYING AN ACETYLCYSTINE DERIVATIVE ZAMBON GROUP S.P.A. (IT) 1996-05-21 — — US disclosed
EP-0499882-A1 Pharmaceutical compositions containing N-acetyl-cysteine derivatives useful for the treatment of cataracts ZAMBON GROUP S.p.A. (IT) 1992-08-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250255843-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF AHCY, MGMT, CBS KDM4E 2170/4885MAPT 2515/4885THRB 3014/4885
US-20060216251-A1 Topical formulations and methods of use CPT1B, SLC25A20, CPT1A KDM4E 2265/4885MAPT 2476/4885THRB 2741/4885
US-20060045896-A1 Topical compositions comprising benfotiamine and pyridoxamine AGER, LPO, LOX KDM4E 1183/4885MAPT 3038/4885THRB 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.